Janux Therapeutics, Inc. (JANX)
NASDAQ:JANX
Want to see JANX full AI Analyst Report?
Total Valuation
Janux Therapeutics Inc has a market cap or net worth of $855.61M. The enterprise value is $847.92M.
Market Cap$855.61M
Enterprise Value$847.92M
Share Statistics
Janux Therapeutics Inc has 60,984,352 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,984,352
Owned by Insiders19.65%
Owned by Institutions44.93%
Financial Efficiency
Janux Therapeutics Inc’s return on equity (ROE) is -0.12 and return on invested capital (ROIC) is -16.01%.
Return on Equity (ROE)-0.12
Return on Assets (ROA)-0.11
Return on Invested Capital (ROIC)-16.01%
Return on Capital Employed (ROCE)-0.16
Revenue Per Employee109.89K
Profits Per Employee-1.25M
Employee Count91
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Janux Therapeutics Inc is ―. Janux Therapeutics Inc’s PEG ratio is -0.18.
PE Ratio―
PS Ratio85.51
PB Ratio0.89
Price to Fair Value0.89
Price to FCF-10.27
Price to Operating Cash Flow-11.64
PEG Ratio-0.18
Income Statement
In the last 12 months, Janux Therapeutics Inc had revenue of 10.00M and earned -113.63M in profits. Earnings per share was -1.83.
Revenue10.00M
Gross Profit7.97M
Operating Income-157.67M
Pretax Income-113.63M
Net Income-113.63M
EBITDA-111.60M
Earnings Per Share (EPS)-1.83
Cash Flow
In the last 12 months, operating cash flow was -77.55M and capital expenditures -945.00K, giving a free cash flow of -78.49M billion.
Operating Cash Flow-77.55M
Free Cash Flow-78.49M
Free Cash Flow per Share-1.29
Dividends & Yields
Janux Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.37
52-Week Price Change-41.87%
50-Day Moving Average14.43
200-Day Moving Average19.05
Relative Strength Index (RSI)49.71
Average Volume (3m)901.59K
Important Dates
Janux Therapeutics Inc upcoming earnings date is Aug 11, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Janux Therapeutics Inc as a current ratio of 39.04, with Debt / Equity ratio of 2.29%
Current Ratio39.04
Quick Ratio39.04
Debt to Market Cap<0.01
Net Debt to EBITDA0.27
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Janux Therapeutics Inc has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Janux Therapeutics Inc EV to EBITDA ratio is -7.39, with an EV/FCF ratio of -9.91.
EV to Sales82.49
EV to EBITDA-7.39
EV to Free Cash Flow-9.91
EV to Operating Cash Flow-10.03
Balance Sheet
Janux Therapeutics Inc has $956.39M in cash and marketable securities with $21.57M in debt, giving a net cash position of $934.82M billion.
Cash & Marketable Securities$956.39M
Total Debt$21.57M
Net Cash$934.82M
Net Cash Per Share$15.33
Tangible Book Value Per Share$15.44
Margins
Gross margin is 54.15%, with operating margin of -1576.67%, and net profit margin of -1136.25%.
Gross Margin54.15%
Operating Margin-1576.67%
Pretax Margin-1136.25%
Net Profit Margin-1136.25%
EBITDA Margin-1115.96%
EBIT Margin-1136.25%
Analyst Forecast
The average price target for Janux Therapeutics Inc is $39.79, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$39.79
Price Target Upside151.49% Upside
Analyst ConsensusStrong Buy
Analyst Count15
Revenue Growth Forecast47.10%
EPS Growth Forecast-35.51%